Alerte De Sécurité sur Software for Surgical / Clinical Planning iPlan. Anvisa Registration n ° 80042070008.

Selon Agência Nacional de Vigilância Sanitária (ANVISA), ce/cet/cette alerte de sécurité concerne un dispositif en/au/aux/à Brazil qui a été fabriqué par Brainlab AG; Brainlab Ltda..

Qu'est-ce que c'est?

Les alertes fournissent des informations importantes et des recommandations concernant les dispositifs médicaux. Le fait qu'une alerte soit émise ne signifie pas nécessairement qu'un dispositif soit dangereux. Les alertes de sécurité, qui sont envoyées tant aux travailleurs du secteur médical qu'aux utilisateurs de ces dispositifs, peuvent inclure des rappels. Elles peuvent être rédigées par des fabricants mais aussi par des autorités en charge de la santé.

En savoir plus sur les données ici
  • Type d'événement
    Safety alert
  • ID de l'événement
    1628
  • Date
    2015-07-10
  • Pays de l'événement
  • Source de l'événement
    ANVISA
  • URL de la source de l'événement
  • Notes / Alertes
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • Notes supplémentaires dans les données
    Automatic calculation of motor units may potentially be incorrect in the Brainlab iPlan RT Dose planning software if all of the following conditions are met: 1 - Multiple PTVs are planned in the treatment plan; 2 - at least one treatment group or treatment element is locked to prevent further modifications; 3 - for each PTV, with a treatment group or at least one locked treatment element, assigned with dose restriction at the point of 50% of the volume deviated by more than 5% from the current dose in the 50% volume. The problem may result in an incorrect treatment plan, which may lead to an incorrect treatment, for example, an overdose in the salivable tissue or sub-dose in the tumor tissue.
  • Cause
    The automatic calculation of motor units may potentially be incorrect in the planning software of the brainlab iplan rt if some conditions of use may lead to incorrect dosing.
  • Action
    The company is developing a new version of software to fix the problem. Recommendations for product users: (1) Carefully check the prescription dialog if the restriction points for all PTVs / boosts are met as expected before approving and exporting, especially if the plan has multiple PTVs / boosts and at least one element / treatment group blocked; (2) Prior to approval and export, the entire plan needs to be reviewed. Note that at any stage the dose distribution in the software reflects the dose actually being delivered by the treatment plan.

Manufacturer

  • Société-mère du fabricant (2017)
  • Source
    ANVSANVISA